Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 3/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.54 |
| ▸ | VIPR2 | P41587 | 6/20 | 0.53 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343041 | 0.86 | CCNA2 (0.57) | CCNA2CDK2CCNA1ESR1VIPR1 | |
| SCHEMBL29933691 | 0.85 | VIPR2 (0.61) | CCNA2CDK2CCNA1ESR1ESR2 | |
| SCHEMBL29736049 | 0.85 | CCNA2 (0.65) | CCNA2CDK2CCNA1VIPR1VIPR2 | |
| SCHEMBL29574453 | 0.83 | PTH1R (0.63) | VIPR1VIPR2PTH1R | |
| SCHEMBL30623152 | 0.83 | VIPR1 (0.68) | VIPR1VIPR2 | |
| SCHEMBL29702256 | 0.82 | CCNA2 (0.69) | CCNA2CDK2CCNA1AGTR1AGTR2 | |
| SCHEMBL23083920 | 0.81 | CCNA2 (0.58) | CCNA2CDK2CCNA1GRIN2DGRIN3B | |
| SCHEMBL29988328 | 0.81 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29375791 | 0.81 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29986050 | 0.81 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724572-A1 | ENGINEERED CELLS WITH ENHANCED TEAD PROTEIN TRANSCRIPTIONAL ACTIVITIES AND METHODS OF USE THEREOF | Legend Biotech Ireland Limited (IE) | 2026-04-15 | — | — | EP | claimed |
| US-12577609-B2 | Methods for cell-type specific profiling to identify drug targets | THE ROCKEFELLER UNIVERSITY (US) | 2026-03-17 | — | — | US | claimed |
| EP-4689188-A2 | ACTIVE SURVEILLANCE AND RISK STRATIFICATION FOR PROSTATE CANCER | Immunis.AI, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-12411144-B2 | Compositions and methods for treatment of lung function | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-09-09 | — | — | US | claimed |
| CN-119464483-A | Probe set for detecting variation of monogenic genetic disease, kit and application | 苏州贝康医疗器械有限公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2024251247-A1 | ENGINEERED CELLS WITH ENHANCED TEAD PROTEIN TRANSCRIPTIONAL ACTIVITIES AND METHODS OF USE THEREOF | NANJING LEGEND BIOTECH CO., LTD. (CN) | 2024-12-12 | — | — | WO | claimed |
| WO-2024238182-A2 | EPIGENETIC SIGNATURE OF T CELL AGING AND MALIGNANCY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| US-20240327927-A1 | ACTIVE SURVEILLANCE AND RISK STRATIFICATION FOR PROSTATE CANCER | IMMUNIS.AI, INC. | 2024-10-03 | — | — | US | claimed |
| WO-2024206495-A2 | ACTIVE SURVEILLANCE AND RISK STRATIFICATION FOR PROSTATE CANCER | IMMUNIS.AI, INC. (US) | 2024-10-03 | — | — | WO | claimed |
| EP-4153995-A2 | DETECTION AND TREATMENT OF CONDITIONS CHARACTERIZED BY PERFUSION SHORTAGE | Falcon Bioscience, LLC (US) | 2023-03-29 | — | — | EP | claimed |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-23 | — | — | US | claimed |
| US-11579140-B2 | Methods related to bronchial premalignant lesion severity and progression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-02-14 | — | — | US | claimed |
| US-11485743-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | claimed |
| CN-109310727-B | Conditionally active heterodimeric polypeptides and methods of use thereof | 加利福尼亚大学董事会 | 2022-09-27 | — | — | CN | claimed |
| US-20220265657-A1 | ADMINISTRATION METHOD AND DOSAGE REGIMEN FOR TREATMENT OF NEURODEGENERATIVE DISEASES USING TRAMETINIB AND MARKERS | GENUV INC (KR) | 2022-08-25 | — | — | US | claimed |
| US-20220234591-A1 | GRIP STRENGTH SMART SLEEVES | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2022-07-28 | — | — | US | claimed |
| WO-2022103282-A1 | NOVEL STEROID HORMONE LIGAND ASSAYS | INSITUGEN LIMITED (NZ) | 2022-05-19 | — | — | WO | claimed |
| WO-2022103283-A1 | NOVEL STEROID HORMONE LIGAND ASSAYS | INSITUGEN LIMITED (NZ) | 2022-05-19 | — | — | WO | claimed |
| CN-110928670-B | Workflow optimization method based on partial sequence adaptive genetic algorithm in cloud computing environment | 浙江工商大学 | 2022-04-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485743-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | CCNA2 3517/4885CDK2 1638/4885CCNA1 3366/4885 |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | CCNA2 3517/4885CDK2 1638/4885CCNA1 3366/4885 |
| US-12577609-B2 | Methods for cell-type specific profiling to identify drug targets | MYL12A, CELF2, RABL3 | CCNA2 2969/4885CDK2 3756/4885CCNA1 3677/4885 |
| US-20220265657-A1 | ADMINISTRATION METHOD AND DOSAGE REGIMEN FOR TREATMENT OF NEURODEGENERATIVE DISEASES USING TRAMETINIB AND MARKERS | PMP22, NGF, NTRK1 | CCNA2 1664/4885CDK2 2406/4885CCNA1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.